+ +

•  

   

     Western blot analysis of CD58 expression in Raji cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

CD58. also known as lymphocyte function-associated antigen 3 (LFA-3), is a cell surface glycoprotein belonging to the immunoglobulin superfamily. It is widely expressed on antigen-presenting cells (APCs), T cells, and various other hematopoietic and non-hematopoietic cells. CD58 interacts with its receptor CD2 on T cells, playing a critical role in stabilizing immune cell interactions, particularly during T cell activation and immune synapse formation. This interaction enhances adhesion between T cells and APCs, facilitating antigen recognition and subsequent immune responses.

CD58-specific antibodies are primarily used as research tools to modulate or block the CD58-CD2 pathway, aiding in the study of T cell activation mechanisms and immune regulation. In therapeutic contexts, anti-CD58 antibodies have been explored for their potential in autoimmune diseases and cancer immunotherapy. For instance, blocking CD58-CD2 signaling may suppress excessive T cell activation in autoimmune disorders, while enhancing anti-tumor immunity by disrupting immune evasion mechanisms exploited by malignancies.

Historically, CD58 was identified in the 1980s as a key player in cell adhesion, with subsequent studies revealing its broader immunomodulatory functions. Monoclonal antibodies targeting CD58 have since been developed, enabling precise investigation of its biological roles. Recent research also explores bispecific antibodies or chimeric antigen receptor (CAR) T cell therapies incorporating CD58-targeting domains to improve immune targeting efficiency. Despite promising preclinical data, clinical applications remain limited, underscoring the need for further studies to evaluate safety and efficacy in humans. Overall, CD58 antibodies represent a valuable tool for dissecting immune pathways and developing novel immunotherapies.